Eli Lilly Gets CDSCO Nod To Study Anti-diabetic Dulaglutide
New Delhi: Pharmaceutical major, Eli Lilly has got the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) approval to study the Phase IV study of anti-diabetic drug Dulaglutide as per the study protocol.This came after the firm presented the protocol for conduct of Phase IV study titled "A 24-week multicenter, open-label, single-arm study...
New Delhi: Pharmaceutical major, Eli Lilly has got the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) approval to study the Phase IV study of anti-diabetic drug Dulaglutide as per the study protocol.
Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular events.
Dulaglutide activates the GLP-1 receptor found in pancreatic beta cells, increasing intracellular cyclic AMP (cAMP) in beta cells, leading to insulin release and subsequent reduction of blood glucose concentrations. Additionally, dulaglutide decreases glucagon secretion and slows gastric emptying.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd